PROGYNY INC (PGNY) Stock Fundamental Analysis
NASDAQ:PGNY - Nasdaq - US74340E1038 - Common Stock - Currency: USD
Overall PGNY gets a fundamental rating of 6 out of 10. We evaluated PGNY against 106 industry peers in the Health Care Providers & Services industry. PGNY scores excellent points on both the profitability and health parts. This is a solid base for a good stock. PGNY is not valued too expensively and it also shows a decent growth rate. These ratings could make PGNY a good candidate for quality investing.
1. Profitability
1.1 Basic Checks
In the past year PGNY was profitable.
PGNY had a positive operating cash flow in the past year.
Each year in the past 5 years PGNY has been profitable.
In the past 5 years PGNY always reported a positive cash flow from operatings.
1.2 Ratios
The Return On Assets of PGNY (8.95%) is better than 93.40% of its industry peers.
PGNY has a Return On Equity of 12.87%. This is in the better half of the industry: PGNY outperforms 78.30% of its industry peers.
PGNY has a Return On Invested Capital of 11.77%. This is amongst the best in the industry. PGNY outperforms 88.68% of its industry peers.
PGNY had an Average Return On Invested Capital over the past 3 years of 8.25%. This is in line with the industry average of 8.79%.
The 3 year average ROIC (8.25%) for PGNY is below the current ROIC(11.77%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 8.95% | ||
| ROE | 12.87% | ||
| ROIC | 11.77% |
ROA(3y)7.58%
ROA(5y)11.89%
ROE(3y)10.72%
ROE(5y)17.23%
ROIC(3y)8.25%
ROIC(5y)7.66%
1.3 Margins
PGNY has a Profit Margin of 4.66%. This is in the better half of the industry: PGNY outperforms 79.25% of its industry peers.
PGNY's Profit Margin has declined in the last couple of years.
With a decent Operating Margin value of 5.78%, PGNY is doing good in the industry, outperforming 65.09% of the companies in the same industry.
PGNY's Operating Margin has improved in the last couple of years.
Looking at the Gross Margin, with a value of 21.71%, PGNY is in line with its industry, outperforming 45.28% of the companies in the same industry.
In the last couple of years the Gross Margin of PGNY has grown nicely.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 5.78% | ||
| PM (TTM) | 4.66% | ||
| GM | 21.71% |
OM growth 3Y-3.61%
OM growth 5Y1.87%
PM growth 3Y-29.25%
PM growth 5YN/A
GM growth 3Y-1.03%
GM growth 5Y1.85%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), PGNY is creating some value.
Compared to 1 year ago, PGNY has less shares outstanding
PGNY has more shares outstanding than it did 5 years ago.
PGNY has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
PGNY has an Altman-Z score of 9.16. This indicates that PGNY is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of PGNY (9.16) is better than 94.34% of its industry peers.
PGNY has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 9.16 |
ROIC/WACC1.31
WACC8.98%
2.3 Liquidity
PGNY has a Current Ratio of 2.80. This indicates that PGNY is financially healthy and has no problem in meeting its short term obligations.
PGNY has a better Current ratio (2.80) than 84.91% of its industry peers.
A Quick Ratio of 2.80 indicates that PGNY has no problem at all paying its short term obligations.
With an excellent Quick ratio value of 2.80, PGNY belongs to the best of the industry, outperforming 85.85% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.8 | ||
| Quick Ratio | 2.8 |
3. Growth
3.1 Past
The earnings per share for PGNY have decreased by -8.06% in the last year.
Measured over the past years, PGNY shows a decrease in Earnings Per Share. The EPS has been decreasing by -4.77% on average per year.
Looking at the last year, PGNY shows a small growth in Revenue. The Revenue has grown by 7.22% in the last year.
The Revenue has been growing by 38.42% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-8.06%
EPS 3Y-4.77%
EPS 5YN/A
EPS Q2Q%-7.69%
Revenue 1Y (TTM)7.22%
Revenue growth 3Y32.6%
Revenue growth 5Y38.42%
Sales Q2Q%10.55%
3.2 Future
Based on estimates for the next years, PGNY will show a very strong growth in Earnings Per Share. The EPS will grow by 32.47% on average per year.
The Revenue is expected to grow by 8.94% on average over the next years. This is quite good.
EPS Next Y1.28%
EPS Next 2Y26.83%
EPS Next 3Y24.48%
EPS Next 5Y32.47%
Revenue Next Year5.56%
Revenue Next 2Y8.41%
Revenue Next 3Y9.95%
Revenue Next 5Y8.94%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
PGNY is valuated quite expensively with a Price/Earnings ratio of 37.61.
PGNY's Price/Earnings ratio is in line with the industry average.
Compared to an average S&P500 Price/Earnings ratio of 28.29, PGNY is valued a bit more expensive.
A Price/Forward Earnings ratio of 37.14 indicates a quite expensive valuation of PGNY.
The rest of the industry has a similar Price/Forward Earnings ratio as PGNY.
The average S&P500 Price/Forward Earnings ratio is at 21.08. PGNY is valued rather expensively when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 37.61 | ||
| Fwd PE | 37.14 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of PGNY is on the same level as its industry peers.
Based on the Price/Free Cash Flow ratio, PGNY is valued cheaply inside the industry as 83.96% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 10.54 | ||
| EV/EBITDA | 21.77 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
PGNY has a very decent profitability rating, which may justify a higher PE ratio.
PGNY's earnings are expected to grow with 24.48% in the coming years. This may justify a more expensive valuation.
PEG (NY)29.29
PEG (5Y)N/A
EPS Next 2Y26.83%
EPS Next 3Y24.48%
5. Dividend
5.1 Amount
PGNY does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
21.44
+0.04 (+0.19%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners99.16%
Inst Owner Change0%
Ins Owners6.69%
Ins Owner Change4.74%
Market Cap1.84B
Analysts77.5
Price Target27.83 (29.8%)
Short Float %15.73%
Short Ratio5.96
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-2.06%
Min EPS beat(2)-19.12%
Max EPS beat(2)15%
EPS beat(4)2
Avg EPS beat(4)5.08%
Min EPS beat(4)-19.12%
Max EPS beat(4)26.05%
EPS beat(8)6
Avg EPS beat(8)31.49%
EPS beat(12)10
Avg EPS beat(12)98.59%
EPS beat(16)14
Avg EPS beat(16)117.36%
Revenue beat(2)1
Avg Revenue beat(2)0.2%
Min Revenue beat(2)-5.35%
Max Revenue beat(2)5.74%
Revenue beat(4)1
Avg Revenue beat(4)-1.95%
Min Revenue beat(4)-5.82%
Max Revenue beat(4)5.74%
Revenue beat(8)4
Avg Revenue beat(8)-0.29%
Revenue beat(12)6
Avg Revenue beat(12)-0.17%
Revenue beat(16)6
Avg Revenue beat(16)-1.1%
PT rev (1m)2.96%
PT rev (3m)44.7%
EPS NQ rev (1m)4.22%
EPS NQ rev (3m)30.27%
EPS NY rev (1m)-6.1%
EPS NY rev (3m)-6.57%
Revenue NQ rev (1m)0.9%
Revenue NQ rev (3m)9.85%
Revenue NY rev (1m)1.23%
Revenue NY rev (3m)4.66%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 37.61 | ||
| Fwd PE | 37.14 | ||
| P/S | 1.57 | ||
| P/FCF | 10.54 | ||
| P/OCF | 10.22 | ||
| P/B | 4.34 | ||
| P/tB | 4.52 | ||
| EV/EBITDA | 21.77 |
EPS(TTM)0.57
EY2.66%
EPS(NY)0.58
Fwd EY2.69%
FCF(TTM)2.03
FCFY9.49%
OCF(TTM)2.1
OCFY9.78%
SpS13.67
BVpS4.94
TBVpS4.74
PEG (NY)29.29
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 8.95% | ||
| ROE | 12.87% | ||
| ROCE | 15.38% | ||
| ROIC | 11.77% | ||
| ROICexc | 24.52% | ||
| ROICexgc | 26.65% | ||
| OM | 5.78% | ||
| PM (TTM) | 4.66% | ||
| GM | 21.71% | ||
| FCFM | 14.88% |
ROA(3y)7.58%
ROA(5y)11.89%
ROE(3y)10.72%
ROE(5y)17.23%
ROIC(3y)8.25%
ROIC(5y)7.66%
ROICexc(3y)19.18%
ROICexc(5y)17.15%
ROICexgc(3y)20.6%
ROICexgc(5y)18.86%
ROCE(3y)10.79%
ROCE(5y)10.01%
ROICexcg growth 3Y11.16%
ROICexcg growth 5Y-10.91%
ROICexc growth 3Y11.54%
ROICexc growth 5Y-2.19%
OM growth 3Y-3.61%
OM growth 5Y1.87%
PM growth 3Y-29.25%
PM growth 5YN/A
GM growth 3Y-1.03%
GM growth 5Y1.85%
F-Score7
Asset Turnover1.92
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 170.24% | ||
| Cap/Sales | 0.46% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 253.58% | ||
| Profit Quality | 319.68% | ||
| Current Ratio | 2.8 | ||
| Quick Ratio | 2.8 | ||
| Altman-Z | 9.16 |
F-Score7
WACC8.98%
ROIC/WACC1.31
Cap/Depr(3y)177.5%
Cap/Depr(5y)150.16%
Cap/Sales(3y)0.4%
Cap/Sales(5y)0.39%
Profit Quality(3y)290.66%
Profit Quality(5y)196.79%
High Growth Momentum
Growth
EPS 1Y (TTM)-8.06%
EPS 3Y-4.77%
EPS 5YN/A
EPS Q2Q%-7.69%
EPS Next Y1.28%
EPS Next 2Y26.83%
EPS Next 3Y24.48%
EPS Next 5Y32.47%
Revenue 1Y (TTM)7.22%
Revenue growth 3Y32.6%
Revenue growth 5Y38.42%
Sales Q2Q%10.55%
Revenue Next Year5.56%
Revenue Next 2Y8.41%
Revenue Next 3Y9.95%
Revenue Next 5Y8.94%
EBIT growth 1Y8.45%
EBIT growth 3Y27.82%
EBIT growth 5Y41.01%
EBIT Next Year25.81%
EBIT Next 3Y17.51%
EBIT Next 5Y15.16%
FCF growth 1Y-6.19%
FCF growth 3Y93.67%
FCF growth 5YN/A
OCF growth 1Y-5.14%
OCF growth 3Y90.18%
OCF growth 5YN/A